Richard Lemons
Pediatric Hematology-Oncology · Salt Lake City, UTNPI 1073692646
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $527,456 of the $753,096 with a category attached, or 70.0%. CSL Behring accounts for 73.5% of it on its own, with 5 other manufacturers making up the rest. Among pediatric hematology-oncology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 804 payments — averaging $936.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$554K
- Novo Nordisk$187K
- Novartis$6K
- Pfizer$6K
- Sanofi$375
- Melinta Therapeutics, LLC$315
Across 222 payments — averaging $5230.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$977K
- Novo Nordisk AS$128K
- Pfizer$40K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
What the payments were for
- Consulting fees$81,44511%
- Speaking & faculty fees$527,45670%
- Travel & lodging$132,81718%
- Food & beverage$11,3782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 668 | $553,675 |
| Novo Nordisk | 124 | $187,490 |
| Novartis | 5 | $5,729 |
| Pfizer | 5 | $5,512 |
| Sanofi | 1 | $375 |
| Melinta Therapeutics, LLC | 1 | $315 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMGENIX$501,041
- Alhemo$53,909
- Esperoct$30,210
- Idelvion$21,010
- REBINYN$10,386
- ADAKVEO$4,904
- NovoSeven$3,987
- Albuminar-25$2,135
- NO PRODUCT DISCUSSED$375
How this compares
$753,096 in reported general payments places this provider in the 95th percentile of 24 pediatric hematology-oncology providers in Utah.
Other pediatric hematology-oncology in Salt Lake City
- Luke MaeseSalt Lake City$332K
- Hassan YaishSalt Lake City$113K
- Julie AschSalt Lake City$62K
- Ahmad RayesSalt Lake City$5K
- Nicholas WhippleSalt Lake City$3K
- Michell Lozano ChingaSalt Lake City$1K
- Soohee ChoSalt Lake City$948
- Joseph DolanSalt Lake City$295
- Mark FluchelSalt Lake City$235
- Elaine FanSalt Lake City$229
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.